Abstract: Objective: Abnormalities in the coagulation pathway play an increasing role in the diagnostic work-up of stroke patients, especially in cases with stroke of undetermined cause. Methods: We investigated three common genetic variants within the coagulation cascade factor V Leiden, prothrombin mutation g.20210 G>A, factor XIII polymorphism Val34Leu in 167 patients with ischemic stroke defined by TOAST subclassification and 500 controls. Results: The factor V Leiden mutation was over-represented in patients with cardioembolic stroke for trend, whereas the prothrombin mutation g.20210G>A as well as the factor XIII polymorphism Val34Leu were not found to be associated with a stroke in general or any stroke subtype. The three polymorphisms showed no association with stroke in subgroups of patients defined by age (<40 y, 40-49 y, 50-59 y, ≥60 y). Discussion: This study suggests that the analysis of prothrombin mutation g.20210 G>A and factor XIII polymorphism Val34Leu is not a useful diagnostic procedure in the work-up of ischemic stroke, and the analysis of the factor V Leiden mutation might only be of some impact in patients with cardioembolic stroke. 
Introduction
The evaluation of coagulation abnormalities plays an important role in the diagnostic work-up of stroke patients, especially when no obvious cause such as a cardiac origin, severe atherosclerosis or any other vascular disease becomes apparent, and when stroke occurs in young patients.
The prothrombin (factor II) mutation g.20210 G>A was described by Poort et al. in 1996 1 and was found to confer a moderately increased risk of venous thrombosis. The factor V Leiden mutation (APC resistance) c.1691 G>A, first described by Bertina et al. in 1994 2 , is associated with recurrent venous thrombosis and thromboembolism, especially in homozygous individuals or when combined with the prothrombin mutation [3] [4] [5] [6] . In a meta-analysis of genetic studies in ischemic stroke, both the prothrombin (19 studies on 3,028 cases and 7,131 controls) and factor V Leiden (26 studies on 4,588 cases and 13,798 controls) mutations were associated with ischemic stroke of any origin with an odds ratio of 1.44 and 1.33 respectively 7 . The factor XIII polymorphism Val34Leu (c.103 G>T [NM_000129.3]) is associated with increased enzyme activity 8, 9 . In some studies, it was negatively associated with myocardial infarction 8 , cerebrovascular disease 10 , or venous thrombosis 11 and positively associated with intracerebral hemorrhage 12 . In other studies, however, no association with coronary heart disease including myocardial infarction, cerebrovascular disease, intracerebral hemorrhage, or deep venous thrombosis was detected 7, 13-17 .
These genetic variables have a considerable allele frequency within the Caucasian population with heterozygosity frequencies of 1-3% for the prothrombin mutation g.20210 G>A, 2-15% for factor V Leiden and 23-50% for factor XIII Val34Leu.
The present study aimed at investigating the effect of these three genetic polymorphisms on the risk of stroke in general and in stroke of different etiologies in a case-control set up. (1) - (3) and artery dissection, and (5) stroke of undetermined etiology. Age subgroups were defined as <40 y, 40-49 y, 50-59 y, ≥60 y. 500 blood donors of German descent (29% female, mean age in years ± standard deviation 33 ± 11) of the University of Bonn were genotyped for the polymorphisms examined. All patients (or their legal trustees) gave informed and written consent; the study was approved by the local ethics committee.
Subjects and methods

Subjects
Genetic analysis
In the genomic DNA samples, factor V Leiden mutation 19 , prothrombin mutation g.20210 G>A 20 , and factor XIII polymorphism Val34Leu 21 were analyzed by TaqMan technique as previously published.
Statistics
For statistics, we applied nominal regression analysis with stroke (respectively the different TOAST subgroups and age subgroups) as dependent variable and age and gender as covariables. Threshold for significance was defined as p < 0.05.
Results
A total of 167 patients were investigated in this study, 69 females and 113 males. Mean age at onset of stroke (± standard deviation) was 55 ± 16 years. Of the 167 patients, 61 were classified into TOAST 1, 47 into TOAST 2, 28 into TOAST 3, 12 into TOAST 4, and in 29 patients the etiology of stroke could not be determined (TOAST 5).
None of the three polymorphisms investigated was associated with a significant risk of ischemic stroke (Table 1 ). Subgroup analysis for the different TOAST groups 1-5 (each in comparison to the healthy control individuals) revealed an over-representation of the factor V Leiden mutation in the group of patients with cardioembolic stroke (TOAST 2) for trend (χ2=5.076; p=0.079). In this subgroup, both other polymorphisms were not associated with the occurrence of stroke, neither was any of the three polymorphisms in all other stroke subgroups. There was no significant association of the polymorphisms with the occurrence of stroke in one of the subgroups defined by age (data not shown).
Discussion
Main findings:
The prothrombin mutation g.20210 G>A and factor V Leiden mutation are known to be associated with a higher risk of venous thrombosis. For the factor XIII polymorphism
Val34Leu, an association with myocardial infarction and cerebrovascular disease has been discussed controversially. We analyzed these three genetic variants in a stroke case-control study. None of the analyzed variants was significantly associated with the risk of stroke. We did not find a significant association of any of the genetic variants with stroke in any TOAST subgroup including class V (stroke of undetermined origin) in our study population. A subgroup analysis of young patients did not reveal a significant influence of any one of the genetic variants, either. The factor V Leiden mutation showed a tendency to predict cardioembolic stroke. This mutation is known to be associated with a risk of thrombosis, thus, a possible underlying mechanism could be paradoxical embolism in patients with patent foramen ovale or embolism in patients with atrial fibrillation.
Comparison with existing literature and limitations of the present study:
Studies concerning the association of ischemic stroke with genetic coagulation factor variants showed contradictory results. In an adult North Mediterranean population younger than 65 years, the prevalences of factor V Leiden and prothrombin 20210G>A mutations were higher in patients with ischemic stroke of any classification compared to controls matched for clinical risk factors 22 . In a recent study encompassing 367 patients with acute ischemic stroke and atrial fibrillation, both the factor V Leiden and the prothrombin g.20210G>A mutation
were no risk factors for stroke associated with atrial fibrillation 23 . Other studies investigating the role of the prothrombin mutation and factor V Leiden mutation in stroke associated with PFO by paradoxical embolism reported contradictory results: Lichy et al. found an association of the prothrombin mutation, but not factor V Leiden mutation, with stroke associated with PFO 24 whereas other studies described an association of both the factor V Leiden mutation and the prothrombin mutation with cryptogenic stroke and PFO 25, 26 . The large meta-analysis of genetic studies in ischemic stroke published by Casas et al. in 2004 encompasses data of 120 case-control studies with approximately 18,000 cases and 58,000 controls 7 . In accordance to our data, no significant association of factor XIII Val34Leu with ischemic stroke was found. For the factor V Leiden and the prothrombin mutations, however, a significant association with ischemic stroke was found with an odds ratio of 1.33 and 1.44 respectively.
In this meta-analysis, only white patients were included, but no other ethnic specification was performed, nor was any subgrouping for stroke etiologies done. Because of our much smaller sample size, minor effects of those two polymorphisms might have been missed in our study.
The implications for future research or clinical practice:
It would be of interest to investigate a larger cohort of patients with known cardioembolic stroke for the factor V Leiden mutation to confirm the association suggested by the present results. Possibly this could be done by retrospectively subgrouping patients according to stroke etiology from existing studies or meta-analyses. Such data could be helpful for strategies to define risk profiles for patients with patent foramen ovale or atrial fibrillation.
In conclusion, our data suggest that these polymorphisms have no major influence on the risk of stroke of any TOAST class. For patients in whom any one of these genetic variants is diagnosed, consequences for treatment are controversial. Thus, genotyping of these variants in patients with ischemic stroke may be of questionable value for the clinical routine at present.
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